Patents by Inventor Raphael STUBER

Raphael STUBER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240189315
    Abstract: The invention relates to compounds of formula I wherein R1, R2, R3, R4, A, D, E, G, J, K and L are defined as in claim 1, and prodrugs, deuterated analogues and pharmaceutical acceptable salts thereof, for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), interferonopathies, non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).
    Type: Application
    Filed: November 3, 2023
    Publication date: June 13, 2024
    Inventors: Annekatrin Charlotte HEIMANN, Christian GNAMM, Cédrickx GODBOUT, Sandra Ruth HANDSCHUH, Christoph HOENKE, Joerg Thomas KLEY, Christian Andreas KUTTRUFF, Jun LI, Dirk REINERT, Raphael STUBER, Theodor THEIS
  • Publication number: 20230000878
    Abstract: The invention relates to new proline derivatives of formula (I) as cGAS inhibitors, wherein wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and G are defined as in claim 1, and prodrugs or pharmaceutically acceptable salts of these compounds for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), non-alcoholic steatotic hepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).
    Type: Application
    Filed: May 10, 2022
    Publication date: January 5, 2023
    Inventors: Annekatrin Charlotte HEIMANN, Sandra Ruth HANDSCHUH, Christoph HOENKE, Cédrickx GODBOUT, Christian GNAMM, Patrick GROSS, Joerg KLEY, Christian Andreas KUTTRUFF, Dirk REINERT, Raphael STUBER
  • Publication number: 20230002401
    Abstract: The invention relates to new proline derivatives of formula (I) as cGAS inhibitors, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and G are defined as in claim 1, and prodrugs or pharmaceutically acceptable salts of these compounds for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), non-alcoholic steatotic hepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).
    Type: Application
    Filed: May 10, 2022
    Publication date: January 5, 2023
    Inventors: Annekatrin Charlotte HEIMANN, Sandra Ruth HANDSCHUH, Christoph HOENKE, Christian GNAMM, Cédrickx GODBOUT, Patrick GROSS, Joerg KLEY, Christian Andreas KUTTRUFF, Dirk REINERT, Raphael STUBER